Evidence map›Paper›PMID 28515133›Full record

ArticleClinical and vaccine immunology : CVI2017

Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.

Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P Zavala, Michael G Rossmann, Sachiko Kuno and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Current advances in the development of SARS-CoV-2 vaccines.International journal of biological sciences · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akane UrakamiVLP Therapeutics, Gaithersburg, Maryland, USA.
Atsuko SakuraiVLP Therapeutics, Gaithersburg, Maryland, USA.
Momoko IshikawaVLP Therapeutics, Gaithersburg, Maryland, USA.
Moh Lan YapDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
Yevel Flores-GarciaDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Yasunari HasedaVaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Taiki AoshiVaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Fidel P ZavalaDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Michael G RossmannDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
Sachiko KunoVLP Therapeutics, Gaithersburg, Maryland, USA.
Ryuji UenoVLP Therapeutics, Gaithersburg, Maryland, USA.
Wataru AkahataVLP Therapeutics, Gaithersburg, Maryland, USA wakahata@vlptherapeutics.com.

Funding

Structural Studies of TogavirusesR01AI095366 · NIAID · PURDUE UNIVERSITY · PI KUHN, RICHARD J. · 2012 to 2023
$6.8M
NIAID NIH HHS R01 AI095366
6 · The paper itself

Abstract

Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's

Indexed as

Drug CarriersAnimalsChikungunya virusDisease Models, AnimalFemaleMacaca mulattaMalariaMalaria VaccinesMaleMice, Inbred BALB CPlasmodium falciparumPlasmodium yoeliiProtozoan ProteinsVaccines, SyntheticVaccines, Virus-Like Particlecircumsporozoite protein, ProtozoanDrug CarriersMalaria VaccinesProtozoan ProteinsVaccines, SyntheticVaccines, Virus-Like Particlealphaviruschikungunya virusmalariavaccinesvirus-like particle

Identifiers

PMID28515133
PMCPMC5498722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.